Laboratory of Endocrinology and Genomics, CHUQ Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, Québec G1V4G2, Canada.
Neurotherapeutics. 2011 Oct;8(4):643-9. doi: 10.1007/s13311-011-0062-0.
A recent phase I/II clinical trial drew serious attention to the therapeutic potential of autologous hematopoietic stem cell transplantation (AHSCT) in multiple sclerosis. However, questions were raised as to whether these beneficial effects should be attributed to the newly reconstituted immune system per se, or to the lymphoablative conditioning regimen-induced immunosuppression, given that T-cell depleting combinational drug therapies were used in the study. We discuss here the possibility that both AHSCT and T-cell depleting therapies may re-program alternatively the immune system, and why transplantation of CD34+ hematopoietic stem cells may offer AHSCT a possible advantage regarding long-term remission.
最近的一项 I/II 期临床试验引起了人们对自体造血干细胞移植（AHSCT）在多发性硬化症中的治疗潜力的高度关注。然而，人们质疑这些有益效果是否应该归因于新重建的免疫系统本身，还是应该归因于淋巴细胞清除性预处理方案诱导的免疫抑制，因为在该研究中使用了 T 细胞耗竭联合药物治疗。我们在这里讨论了 AHSCT 和 T 细胞耗竭疗法都可能重新编程免疫系统的可能性，以及为什么 CD34+造血干细胞移植可能为 AHSCT 提供长期缓解的优势。
